2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene CAS 898566-17-1 Purity >98.0% (HPLC)

Chemical Name: 2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene  CAS: 898566-17-1 Purity: >98.0% (HPLC) Appearance: White to Pale Yellow Crystalline Powder E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureManufacturer Supply Related Intermediates: 4-Fluorophenylboronic Acid CAS: 1765-93-1 2-(4-Fluorophenyl)thiophene CAS: 58861-48-6 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone CAS: 32384-65-9 5-Iodo-2-Methylbenzoic Acid CAS 54811-38-0 2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene CAS: 1030825-20-7 2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene CAS: 898566-17-1 CAS: 842133-18-0 CAS: 928672-86-0
Item Specifications
Appearance White to Pale Yellow Crystalline Powder
Purity / Analysis Method >98.0% (HPLC)
Loss on Drying <1.00%
Total Impurities <2.00%
Test Standard Enterprise Standard

Description:

Specifications:

Package & Storage:

Chemical Name 2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene
CAS Number 898566-17-1
CAT Number RF-PI1501
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C18H14FIS
Molecular Weight 408.27
Melting Point 109.0~110.0℃
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene (CAS: 898566-17-1) is an antidiabetic agent and an intermediate of API (CAS: 842133-18-0). (CAS: 842133-18-0) is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and a candidate for the treatment of type 2 diabetes and obesity. (CAS: 842133-18-0) is a once daily oral diabetes drug, which works by inhibiting sodium glucose co-transporter 2 (SGLT2) as a new drug. (CAS: 842133-18-0) can lower blood glucose levels by interdicting the blood glucose reabsorption of the kidneys and increasing the excretion of blood glucose in urine. It is the first FDA approved inhibitor for SGLT2 and used to treat adult patients with type 2 diabetes.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours